Steven Reichling - 13 Mar 2023 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
15 Mar 2023, 14:15:49 UTC
Prior SEC filing
13 Mar 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Steve Reichling

Key filing fact

Steven Reichling filed Form 4 for Accelerate Diagnostics, Inc (AXDX) on 15 Mar 2023.

Key facts

  • This page summarizes Steven Reichling's Form 4 filing for Accelerate Diagnostics, Inc (AXDX).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 15 Mar 2023, 14:15.

Change

  • Previous filing in this sequence was filed on 13 Mar 2023.
  • Current net transaction value: -$2,307.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXDX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+9,438
Change %
+6.9%
Price
$0.000000
Shares after
147,078
Date
13 Mar 2023
Ownership
Direct
Footnotes
F1
AXDX transaction

Common Stock

Sale

Transaction value
$2,307
Shares
-4,708
Change %
-3.2%
Price
$0.4900
Shares after
142,370
Date
13 Mar 2023
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXDX transaction Derivative

Employee Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-9,438
Change %
-100%
Price
$0.000000*
Shares after
0
Date
13 Mar 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,438
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. On March 13, 2021, the reporting person was granted a total of 113,265 restricted stock units, which vests in equal amounts every month for 12 months.

Footnote F2

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .